Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:12:47 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

IRLAB Q2 2023 - Mesdopetam returns to IRLAB

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

IRLAB Q2 2023 - Mesdopetam returns to IRLAB

2023-09-01 08:45:00

Redeye updates its view of IRLAB following the Q2 report and additional Mesdopetam data. We argue that the risk reward of future development of Mesdopetam depends on regulatory feedback from the FDA. Regardless, we argue that there is plenty of value in the company beyond Mesdopetam, including the independent asset Pirepemat (with phase IIb readout expected in 2024) and the research engine ISP.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/